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Abstract: Venomous mammals are rare, and only a few species in the orders Insectivora and
Monotremata produce toxic venom. Among them, the duckbill platypus (Ornithorhynchus
anatinus) is one of the two venomous Australian mammals. The adult male platypus carries
a spur on each hind leg, which it uses to inject competitors with poison. However, the struc-
ture and function of the poison’s active compounds are still imcompletely characterized. We
found that crude platypus venom produced potent Ca2+ influx in human neuroblastoma
IMR-32 cells. Guided by this assay, we identified 11 unique peptides, including peptide
H–His–Asp–His–Pro–Asn–Pro–Arg–OH, which coincided with the N-terminal domain
residues of Ornithorhynchus venom C-type natriuretic peptide (OvCNP). This heptapeptide
induced a significant increase in [Ca2+]i in IMR-32 cells at 75 μM; had relatively specific
affinities for glutamate, histamine, and GABAA receptors; and facilitated neurogenic twitch-
ing in guinea pig ileum specimens at 30 μM. We also established that its proteinous venom
fraction strongly hydrolyzed Pro–Phe–Arg–MCA and cleaved a human low-molecular-
weight kininogen (LK), similar to porcine pancreas kallikrein. These results strongly indi-
cated that platypus venom contains tissue kallikrein-like protease(s), and its proteolytic activ-
ity might synergistically contribute to toxicity through the specific cleavage of other venom
constituents.
Keywords: bioactive molecules; chemical ecology; mass spectrometry; mammalian venom;
natural products.
INTRODUCTION
Many toxic constituents from lower animals, such as insects, lizards, and snakes, have been well char-
acterized. However, venomous mammals are quite rare, and only a few species, such as shrews and the
solenodon (Insectivora), as well as the duckbill platypus (Monotremata), are known to produce toxic
venom [1]. Since the disappearance of dinosaurs (~65 million years ago), these venomous mammals are
believed to have evolved with little change in morphology. Interestingly, among living mammals, only
these most ancient species produce toxic venom. Thus, identification of the unique bioactive substances
in mammalian venoms should help to clarify their evolutional properties and ecological roles. Owing
to their instability as well as the difficulty of collecting fresh venom fluid or venomous gland specimens
in sufficiently large amounts, mammalian venoms have not been well characterized. However, now that
the recent advancements in spectroscopic analyses and genetic approaches are available, we have
sought to isolate scarce, unstable, and composite toxic substances of mammalian origin. 
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Shrews have both the smallest size and the highest metabolic rates among mammals. Venomous
shrews are known to not only eat worms and insects, but also to attack vertebrates, even larger than
themselves [2]. For example, the short-tailed shrew Blarina brevicauda feeds on murid rodents and
frogs [3–5]. The semi-aquatic shrew Neomys fodiens feeds on frogs, newts, and small fish. Therefore,
these shrew species may use venom to effectively catch and immobilize large prey to meet their own
high metabolic demands [6,7]. We previously identified blarina toxin (BLTX), lethal venom with a tis-
sue kallikrein-like activity, from the salivary glands of B. brevicauda. Mice that were administered
BLTX i.p. developed irregular respiration, paralysis, and convulsions before dying [8–10]. Homology
modeling studies of BLTX revealed that most of the amino acid residues in BLTX highly overlapped
those of human tissue kallikrein, including presumed catalytic site residues [11,12].
Meanwhile, the duckbill platypus, Ornithorhynchus anatinus, is one of the two venomous
Australian mammals (Fig. 1) [13]. The adult male platypus carries a spur on each hind leg, which it uses
to inject competitors with poison. Envenoming by a platypus causes immediate, excruciating pain in
humans, which evolves toward a long-lasting hyperalgesia (hypersensitivity to pain). Since the end of
the 19th century, several constituents of the platypus venom fluid or its crural gland have been identi-
fied [14–16]. Recently, several Australian chemists and biologists have made special efforts to identify
and characterize the unique venom constituents [17–19]. They include defensin-like peptides [20–23],
C-type natriuretic peptides (OvCNPs) [24–26], nerve growth factor (NGF), and hyaluronidase. In addi-
tion, an L-to-D-peptide isomerase has been identified, by which D-Leu2 in OvCNPs and D-Met2 in
defensins are formed [27–30]. While this platypus peptide isomerase was the first identified one of
mammalian origin, it was recently shown that this enzyme is also contained in mouse heart and echidna
venom [31,32]. However, the specific neurotoxic substances in platypus venom that lead to excruciat-
ing pain are still incompletely characterized.
In 2008, the platypus genome project was completed. It revealed that the platypus genome con-
sists of 18500 protein-coding genes, and shows reptilian, avian, and mammalian features [33,34].
Various “blueprints of life” have been unveiled in animals ranging from insects to humans. However, to
clarify complex and dynamic living systems, it is essential that we investigate the structures and func-
tions of the true bioactive molecules in venom systems. 
As mentioned in the previous reviews, we have focused on the identification of natural key com-
pounds that control biologically and physiologically intriguing phenomena [35–39]. Recently, we had
the opportunity to obtain fresh platypus venom, with the kind cooperation of Taronga Zoo, Sydney,
Australia, and identified picomole amounts of several unique peptides in this venom fluid [40]. This
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Fig. 1 Duckbill platypus and its venom apparatus (photo credit: left, Taronga Zoo; right, Dr. Vogelnest). 
review discusses the identification, biological activities, and biosynthesis of these peptides, as well as
an investigation of the proteinous components in platypus venom. 
RESULTS AND DISCUSSION
Identification and structures of peptides in platypus venom 
With fresh platypus venom fluid in hand, various bioassays were carried out. Intravenous or intra -
cerebral administration in mice did not produce any significant symptoms, and no hemolytic activity
was observed against rabbit or sheep red blood cells. However, the venom produced potent Ca2+ influx
in human neuroblastoma IMR-32 cells [11]. Notably, unlike the rapid temporary increase in [Ca2+]i
(internal calcium ion) caused by KCl, the calcium uptake caused by 1 was slow and continuous. Thus,
we anticipated that platypus venom might contain some physiologically important neurotoxic sub-
stances. 
Since platypus venom contains molecules of various sizes, we first chose gel-permeation high-per-
formance liquid chromatography (HPLC) for purification, and the lower-molecular-weight components,
fraction IX (discussed below), showed Ca2+ influx activity. Further purification by reverse phase HPLC
gave peptide 1 as a primary component (~200 ng/μL venom fluid) (Fig. 2) [41]. Through the use of
matrix-assisted laser desorption/ionization with time-of-flight mass spectrometry (MALDI-TOF/TOF
MS) analysis, the primary structure of 1 was established to be H–His–Asp–His–Pro–Asn–Pro–Arg–OH,
which coincided with the N-terminal domain residues of platypus CNP [40]. CNPs are vasorelaxant pep-
tide hormones that are widely expressed in vivo, including the central nervous system [42]. OvCNPs
cause the relaxation of rat uterine smooth muscle, promote histamine release from mast cells, and form
fast cation channels in lipid bilayers [24,43–45]. This is the first example of the isolation of N-terminal
domain residues of CNPs in any mammal.
Furthermore, direct HPLC purification of crude platypus venom afforded peptides 3 and 4 as
major constituents [46]. By comparing the retention times of synthetic and natural peptides, we con-
firmed that the Leu2 residues in both peptides were of the D-form. Furthermore, a hexapeptide 2, pep-
tides 5–8, and peptides 9–11 were purified from the fr. VI as major constituents. Peptides 2–4 were
analogs of 1, which coincided with the 6–9 N-terminal domain residues of OvCNP. Meanwhile, pep-
tides 5–9 corresponded to the 132–150 part of OvCNP precursor peptide (pre-OvCNP). The y-ion frag-
ment patterns in MS/MS data suggested that the 12 C-terminal residues in peptides 10 and 11 were
identical to those in 9, but their molecular mass units were 17 less and 1 more than those of pre-OvCNP
(132–150), respectively. Further detailed MS/MS analysis revealed that 10 had a cyclic amide structure
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Fig. 2 Amino acid sequences of platypus venom peptides. Common sequences in the N-terminal domain CNP
fragment peptides 1–4 and the CNP precursor fragment peptides 5–11 are highlighted. 
at the N-terminal Ala1–Asn2 moiety by deamidation (Fig. 3) [47], while the amide moiety of the Asn2
residue was hydrolyzed to an Asp residue in 11. 
Biological activities of peptides in platypus venom 
Synthetic heptapeptide 1 showed significant Ca2+ influx activity in IMR-32 cells at 75 μM [40]. Unlike
the fast and temporary increase in [Ca2+]i caused by KCl, the calcium uptake caused by 1 was slow and
continuous, which was identical to the result with crude venom. In addition, among peptides 1–9, only
heptapeptide 1 produced prominent inflammation (s.c. injection, 1 mg per 10 g mice) and shaking
behavior (intracerebral injection, idem) [48,49].
We used differentiated IMR-32 cells that expressed L- and N-type voltage-gated calcium chan-
nels (VGCCs). Based on the results of various receptor-binding assays, however, heptapeptide 1 did not
significantly bind to L- or N-type VGCCs, potassium channels (KA and KATP, hERG), or a sodium
channel (site 2) at 10 μM (Table 1). These results suggested that the venom peptide 1 may not directly
activate known voltage-gated ion channels, but may specifically bind to other receptor channels or bio-
macromolecules. Indeed, among the various receptors tested that are related to pain, inflammation, or
neurotransmission, 1 had relatively specific affinities for glutamate, histamine H1, and GABAA recep-
tors. 
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Fig. 3 MALDI-TOF/TOF MS analysis of natural 10 [precursor ion: 1963.4 (M+H)+]. Observed fragment y-ion
peaks cleaved from the C-terminus and b-ion peaks from the N-terminus are denoted in the upper and lower lanes,
respectively. The order of P+K (proline and lysine) could not be experimentally determined owing to the relatively
resistance to the fragmentation of proline peptide bonds. This was estimated from the genome sequence of pre-
OvCNP. 
Table 1 Receptor binding assays of peptide 1. 
Receptor Inhibition (%)
Adrenergic α1 6
Adrenergic α2 3
Adrenergic β –3
Bradykinin B1 –8
Bradykinin B2 –5
Calcium channel L-type, benzothiazepine –16
Calcium channel L-type, dihydropyridine 4
Calcium channel L-type, phenylalkylamine –17
Calcium channel N-type 1
Cannabioid CB1 –1
Cannabioid CB2 –10
Chemokine CCR1 4
Chemokine CXCR1/2 2
Cholecystokinin CCK2 5
Dopamine D1 –14
Dopamine D2L 4
GABAA, chloride channel, TBOB 3
GABAA, flunitrazepam, Central 21
GABAA, muscimol, central 9
Glutamate, kainate 16
Glutamate, NMDA, phencyclidine 0
Histamine H1 11
Neuropeptide Y Y1 –7
Neurotensin 0
Nicotinic acetylcholine α1, bungarotoxin –5
Opiate δ (OP1, DOP) –15
Opiate κ (OP2, KOP) 4
Opiate μ (OP3, MOP) 1
Orphanin ORL1 8
Potassium channel [KA] 1
Potassium channel [KATP] –3
Potassium channel hERG –14
Serotonin 5-HT1 –12
Serotonin 5-HT2 –8
Sodium channel site 2 –12
Tachykinin NK1 –16
Vanilloid –2
Substrate concentration = 10 μM. 
Next, we compared the receptor antagonism activities of 1 and its analogs 3, 4, and 4' (an L-Leu2
analog of 4) for the selected receptors described above (Fig. 4). Among glutamate receptors, while nat-
ural peptides 1, 3, and 4 all bound similarly to kainate-type receptors, different affinities were observed
for NMDA-type. It is interesting how these binding specificities can be linked to the neurotoxicity of 1
or kainic acid in mice. Furthermore, heptapeptide 1 facilitated a neurogenic twitching in guinea pig
ileum specimens at 30 μM. Thus, compound 1 was found to have agonist activity at histamine H1 or
GABAA receptors, which might be related to its inflammatory activity in mice. 
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Protease activity and SDS-PAGE analysis of platypus venom
Since the C-termini of several platypus venom peptides, 1, 2, and 4–8, were free arginine residues
(Fig. 2), we anticipated that platypus venom had trypsin or kallikrein-like protease activity. Indeed, a
proteinous venom fraction, especially fr. II, strongly hydrolyzed Pro–Phe–Arg–MCA, a fluorescent
peptide substrate of tissue kallikrein (Fig. 5a). 
We also examined the in vitro kininogen cleavage activities of platypus venom. On sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, fr. II degraded a human low-
molecular-weight kininogen (LK) in a time-dependent manner (Fig. 6a). The degradation products
resulting from incubation with fr. II appeared to be identical to those obtained by incubation with
porcine pancreatic kallikrein (PPK). Furthermore, these degradations were markedly suppressed by the
serine protease inhibitor aprotinin (bovine pancreatic trypsin inhibitor). These observations strongly
indicated that platypus venom contains tissue kallikrein-like protease(s). 
Tissue kallikrein (EC 3.4.21.35) cleaves diverse polypeptide precursors such as kininogens, epi-
dermal growth factor, NGF, and angiotensinogen, and also liberates biologically active peptides in vitro
[50]. This enzyme is uniquely characterized by its ability to hydrolyze two specific and distinct peptide
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Fig. 4 Receptor antagonism assays of platypus CNP fragment peptides. Substrate concentration = 10 μM. Values
of the inhibitory effects (%) are shown in the bar graph. ND = no data. 
Fig. 5 Purification of the proteins in platypus venom. (a) Gel-permeation HPLC of venom fluid (5 μL). The effect
of each fraction on Ca2+ influx (blank column) and the peptidase activity (Pro–Phe–Arg–MCA, ) of each fraction
are shown. (b) SDS-PAGE analysis of the proteins in platypus venom. Fr. I–V (1/100 amount) was loaded and
proteins were detected by silver staining. 
bonds, Met-Lys (human) or Lys-Arg (mouse), and Arg-Ser (all mammals), within kininogens to release
lysyl-bradykinin (kallidin) or bradykinin (BK), respectively (Fig. 6b). Liberated kinins potently relax
vascular smooth muscle, increase vasodilation, and enhance vascular permeability [51,52]. Thus, it has
been suggested that the kallikrein-kinin system may play an important role in blood pressure homeo -
stasis and pain. It was found that the lethal venom of Blarina shrew, BLTX, converts kininogens to
kinins. Furthermore, both the acute toxicity in mice and proteolytic activity of BLTX are strongly inhib-
ited by aprotinin, which suggests that its toxicity is due to a kallikrein-like activity of the venom [8,9].
Several kallikrein-related proteases, including gila toxin (GTX) and horridum toxin (HTX), have been
isolated as lethal factors from lizards [53,54]. Both of these toxins have hypotensive effects when
injected into rats, and are also hemorrhagic, yet only HTX causes exophthalmia (protrusion of the eyes)
[55]. While platypus venom is not lethal in mice, it is interesting that all of these venomous vertebrates
produce and use such similar secretory serine proteases.
In an SDS-PAGE analysis of the higher-molecular-weight components of platypus venom, sev-
eral proteins were detected between fr. II–IV (Fig. 5b). It was established that by the detailed MS/MS
analysis of the tryptic peptide fragments obtained by an in-gel digestion, two major proteins in fr. III
were α-trypsin inhibitor (α1TI, 51 kDa) and lactoferrin (80 kDa), respectively [56]. Meanwhile,
kallikrein-like protease(s) were present in very minute amounts, and have not yet been identified, but
might correspond to a single 48-kDa band of the first half of fr. II. 
A cDNA library from its venom gland was constructed by the researchers who decoded the platy-
pus genome [57]. Based on its transcriptome data, 83 putative platypus venom peptides/proteins in 13
different families were identified, and interestingly, the largest group consisted of serine proteases. Most
recently, gene duplications and the expression of transcripts were analyzed in an in-season platypus
venom gland, which included several serine proteases, metalloproteinases, and protease inhibitors [58].
It was noteworthy that serine proteases (kallikrein and other) and Kunitz-type protease inhibitors
(α1TI), which are likely to produce symptoms associated with envenomation such as vasodilation and
pain, were found to be contained in platypus venom based on both gene expression and secreted mature
protein levels. 
Biosynthesis of peptides in platypus venom 
While the real targets of platypus kallikrein are still unknown, we expected that its proteolytic activity
might synergistically contribute to toxicity through the specific cleavage of other venom constituents.
Figure 7 summarizes a proposed biosynthesis of venom peptides. It is reasonable that OvCNP-39a is
formed from a precursor, pre-OvCNP (208 amino acids), and that the Leu2 residue is partially isomer-
ized into the D-form to give 39b [27]. Meanwhile, the N-terminal domain CNP fragment peptides 1, 3,
and 4 may be formed by the specific degradation by kallikrein-like protease(s) and dipeptidyl pepti-
dases.
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Fig. 6 Kininogen cleavage activity of platypus venom. (a) SDS-PAGE analysis of the degradation of LK by fr. II
or PPK at various time intervals, and its inhibition by aprotinin (10 μM). Band a, LK (64 kDa); band b, degraded
products (59 kDa). (b) Schematic representation of the hydrolysis and resulting fragmentation of LK. 
CNPs are some of the most well characterized peptide hormones among a wide range of verte-
brates. The amino acid sequences of mammalian CNPs, such as human CNPs (hCNP-53, -22) and
mouse CNP, are highly conserved, and a disulfide bond between two cysteine residues in the C-termi-
nus has been shown to be essential for their activities. However, we think that these CNPs in mammals
may commonly be further degraded to give diverse physiologically active substances. If so, it is possi-
ble to find various bioactive fragment peptides that are derived not only from CNPs, but also from other
well-characterized peptide hormones and proteins. 
CONCLUSION
Owing to the interesting ecology of venomous mammals, we examined the constituents of platypus
venom. We identified unique neurotoxic peptides and demonstrated the presence of kallikrein-like pro-
tease(s). The present findings may lead to the development of valuable vasoactive or pain-relief agents,
and to a deeper understanding of the biological evolution of vertebrates in relation to toxic substances.
Further studies on the target biomacromolecules of the venom constituents found in this study and on
their functions that lead to neurotoxic symptoms are currently underway. 
EXPERIMENTAL
Venom collection
The duckbill platypus venom project was conducted on property owned by the Zoological Parks Board
of New South Wales, Australia. Platypus venom was collected from a male platypus (bodyweight
1~1.5 kg) under anesthesia at the Taronga Zoo, Sydney, Australia, in October 2005 (spring, breeding
season) and April 2006 (autumn). The muscles around the crural gland and venom resavoir were mas-
saged and droplets of venom were aspirated from the tip of each spur using an Eppendorf micropippete
according to the reference [24]. The collected venom (totally ~15 μL), a clear viscous fluid, was imme-
diately frozen under liquid nitrogen and then stored at –70 °C until use. 
Purification of the platypus venom peptides
Separation of the bioactive substances in platypus venom was performed as described previously [40].
In brief, 5 μL of platypus venom fluids (corrected in the breeding season) were diluted 10-fold with ice-
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Fig. 7 Proposed biosynthesis of peptides in platypus venom. D-Leu residues are highlighted in black. Conserved
cysteine residues are also highlighted. An asterisk indicates an amino acid residue that is identical between OvCNP
and hCNPs. 
cold 0.1 M NH4OAc, loaded on a TSKgel G2000SWXL column (7.8 mm I.D. × 300 mm, TOSOH Co.,
Osaka, Japan), and eluted with 0.1 M NH4OAc at a flow rate of 0.2 mL/min, with monitoring at 280 nm
at 4 °C. Twenty fractions were collected from 20 to 120 min, and every two fractions were combined
to give 10 fractions, fr. I–X (Fig. 5a). 2/5 amounts of each fr. I–X were freeze-dried, dissolved in water
(100 μL), and freeze-dried again. This step was repeated twice to remove the remaining ammonium
acetate. The lyophilized samples were subjected to cell-based Ca2+ influx assays and SDS-PAGE analy-
sis (Fig. 5b). 
2/5 amounts of fr. IX were loaded on a C30 Develosil RP-AQEUOUS AR-5 semi-micro column
(1.5 mm I.D. × 150 mm, Nomura Chemical Co., Aichi, Japan) at 20 °C. A linear gradient of 0–25 %
aq. MeCN for 120 min containing 0.05 % TFA was applied at a flow rate of 100 μL/min to give hepta -
peptide 1 (~400 ng). Similarly, 1/20 amount of fr. VI was separated to give hexapeptide 2 (~20 ng), a
mixture of peptides 5–8 (total ~40 ng), and a mixture of peptides 9–11 (total ~30 ng), respectively.
Furthermore, 1 μL of the platypus venom fluid (corrected in the breeding season) was separated to give
heptapeptide 3 (~200 ng) and nonapeptide 4 (~50 ng), respectively. 
Enzyme assay
Enzyme activity using the Pro-Phe-Arg-MCA substrate was analyzed with a Hitachi F-4500 fluores-
cence spectrophotometer by measuring the amount of 4-amino-7-methyl-coumarin (AMC) released,
with excitation and emission wavelengths of 370 nm and 460 nm, respectively, at 37 °C, as previously
described [8]. One unit was defined as 1 μmol of AMC released from peptidyl-MCA substrates per
minute, at 37 °C. 
The degradation of kininogens was measured by incubating 0.2 mg/mL LK in 50 mM TrisHCl
buffer (pH 8.5) with platypus venom fr. II (3.3 μL, 2 mU) or PPK (14 ng, 2 mU) at 37 °C, with a reac-
tion mixture volume of 20 μL. At 0, 10, 30, and 60 min, 5 μL of the reaction mixture was withdrawn
and added to 5 μL of denaturing solution, as previously described [8,9]. After the samples were boiled
for 5 min, SDS-PAGE was performed using a precast 10 % polyacrylamide gel (ATTO Co., Tokyo,
Japan), and the gels were stained with a Silver Stain Kit, Protein (Amersham). To determine the inhi-
bition of enzymatic activity by a protease inhibitor, the platypus venom fr. II or PPK (0.5 mU each) was
incubated with 10 μM aprotinin for 5 min at 37 °C before use. 
In-gel digestion
After SDS-PAGE, gels were silver-stained in a mass-compatible manner as described in the literature
[59,60]. Stained spots were excised from a PAGE gel, and the gels were desilverized and dehydrated,
and the proteins were carbamidomethylated according to the manufacturer’s protocol. The gels were
incubated with a sequence-grade modified trypsin [1:100 (w/w)] (#V5111, Promega) in 25 mM ammo-
nium bicarbonate at 37 °C for 19 h as described previously [8]. The tryptic peptide mixtures were
extracted from the gel and desalted using a pipette-attached tip column (Zip-Tip C18, Millipore) for MS
and MS/MS analyses. MALDI-TOF MS was performed using a Bruker ultrafleXtreme spectrometer
with α-cyano-4-hydroxycinnamic acid as a matrix. 
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